Sinsin Pharmaceutical (A002800) Stock Overview
Manufactures and sells pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
A002800 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Sinsin Pharmaceutical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,900.00 |
| 52 Week High | ₩8,730.00 |
| 52 Week Low | ₩5,020.00 |
| Beta | 0.22 |
| 1 Month Change | 5.36% |
| 3 Month Change | 2.25% |
| 1 Year Change | 5.36% |
| 3 Year Change | 17.30% |
| 5 Year Change | -30.42% |
| Change since IPO | -26.43% |
Recent News & Updates
Recent updates
Sinsin Pharmaceutical (KOSDAQ:002800) Takes On Some Risk With Its Use Of Debt
Apr 08
What Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) 40% Share Price Gain Is Not Telling You
Jul 30Sinsin Pharmaceutical's (KOSDAQ:002800) Profits May Not Reveal Underlying Issues
Mar 20What Kind Of Shareholders Hold The Majority In Sinsin Pharmaceutical Co., Ltd's (KOSDAQ:002800) Shares?
Mar 06Is Sinsin Pharmaceutical (KOSDAQ:002800) A Risky Investment?
Feb 08
If You Had Bought Sinsin Pharmaceutical (KOSDAQ:002800) Stock A Year Ago, You Could Pocket A 24% Gain Today
Jan 18We're Not Counting On Sinsin Pharmaceutical (KOSDAQ:002800) To Sustain Its Statutory Profitability
Dec 25What Kind Of Investors Own Most Of Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)?
Nov 29Shareholder Returns
| A002800 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 7.5% | 6.6% | 3.9% |
| 1Y | 5.4% | 48.7% | 138.3% |
Return vs Industry: A002800 underperformed the KR Pharmaceuticals industry which returned 48.7% over the past year.
Return vs Market: A002800 underperformed the KR Market which returned 138.3% over the past year.
Price Volatility
| A002800 volatility | |
|---|---|
| A002800 Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.3% |
| 10% least volatile stocks in KR Market | 4.6% |
Stable Share Price: A002800 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A002800's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1959 | 351 | Ki Lee Byoung | www.sinsin.com |
Sinsin Pharmaceutical Co., Ltd manufactures and sells pharmaceutical products in South Korea. It offers various medicinal products, such as plaster, aerosol, topical liquid, emollient, hygiene, and ointment products, as well as adhesive bandages, mosquito repellents, anti-perspirants, cooling sheets, bruise treatment creams, and other products. The company also develops transdermal drug delivery system, and bag on valve inhaler and aerosol solubilzation system.
Sinsin Pharmaceutical Co., Ltd Fundamentals Summary
| A002800 fundamental statistics | |
|---|---|
| Market cap | ₩87.99b |
| Earnings (TTM) | ₩9.29b |
| Revenue (TTM) | ₩113.78b |
Is A002800 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A002800 income statement (TTM) | |
|---|---|
| Revenue | ₩113.78b |
| Cost of Revenue | ₩70.77b |
| Gross Profit | ₩43.01b |
| Other Expenses | ₩33.72b |
| Earnings | ₩9.29b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 612.51 |
| Gross Margin | 37.80% |
| Net Profit Margin | 8.17% |
| Debt/Equity Ratio | 58.4% |
How did A002800 perform over the long term?
See historical performance and comparisonDividends
Does A002800 pay a reliable dividends?
See A002800 dividend history and benchmarks| Sinsin Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Dec 29 2025 |
| Dividend Pay Date | Apr 17 2026 |
| Days until Ex dividend | 109 days |
| Days until Dividend pay date | 0 days |
Does A002800 pay a reliable dividends?
See A002800 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/16 12:00 |
| End of Day Share Price | 2026/04/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sinsin Pharmaceutical Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.